Cargando…
Expert opinion on the use of cladribine tablets in clinical practice
BACKGROUND: Gaps in current product labels and a lack of detailed clinical guidelines leaves clinicians’ questions on the practical management of patients receiving cladribine tablets for the treatment of relapsing multiple sclerosis (MS) unanswered. We describe a consensus-based programme led by in...
Autores principales: | Sørensen, Per Soelberg, Centonze, Diego, Giovannoni, Gavin, Montalban, Xavier, Selchen, Daniel, Vermersch, Patrick, Wiendl, Heinz, Yamout, Bassem, Salloukh, Hashem, Rieckmann, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318823/ https://www.ncbi.nlm.nih.gov/pubmed/32636933 http://dx.doi.org/10.1177/1756286420935019 |
Ejemplares similares
-
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
por: Rieckmann, Peter, et al.
Publicado: (2021) -
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets
por: Yamout, Bassem I, et al.
Publicado: (2022) -
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
por: Giovannoni, Gavin, et al.
Publicado: (2018) -
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study
por: Comi, Giancarlo, et al.
Publicado: (2018) -
Effects of cladribine tablets on lymphocyte subsets in patients with
multiple sclerosis: an extended analysis of surface markers
por: Stuve, Olaf, et al.
Publicado: (2019)